The combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line
treatment for PD-L1-positive metastatic triple-negative breast cancer (mTNBC), based on the …

Background: The effectiveness of atezolizumab plus nab-paclitaxel for advanced triple-
negative breast cancer (TNBC) has been demonstrated. We aimed to evaluate its cost …

The lack of effective therapies for metastatic triple‐negative breast cancer (mTNBC)
highlights the need for the development of novel treatment strategies. The cornerstone of …

Background Guidelines recommend atezolizumab plus nab-paclitaxel (A+ nP) for first-line
treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer …

The PD-L1 inhibitor atezolizumab received US FDA accelerated approval as treatment for
PD-L1-positive metastatic triple-negative breast cancer (TNBC). In IMpassion130, combining …

Immunotherapy (IO) is rapidly reshaping the treatment landscape for solid tumors, with
survival improvements demonstrated in multiple disease types. In the context of metastatic …

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast
cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled …

Background: Metastatic triple-negative breast cancer (mTNBC) is associated with poor
prognosis, and chemotherapy remains the mainstay of treatment. Cancer immunotherapy …